Aclaris reports Q1 net loss $16.9M, down 40% YoY; advances ATI-2138 into Phase 2a for AD

Aclaris Therapeutics, Inc.

2024-Q1 EPS reported -$0.24 revenue$2,398,000

Net loss narrowed to $16.9M from $28.2M YoY; total revenue $2.4M, flat.
Cash and marketable securities $161.4M at March 31, 2024; expects lower quarterly cash burn ahead.
Progressing ATI-2138 (ITK/JAK3 inhibitor) into Phase 2a proof-of-concept trial for moderate-to-severe atopic dermatitis.
Seeking global development partner for lepzacitinib (topical JAK 1/3 inhibitor) after positive Phase 2b AD data.
R&D expenses fell to $9.8M from $22.6M, driven by wind-down of programs and workforce reduction.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aclaris Therapeutics, Inc. reported first quarter of 2024 results: revenue $2.4 million, net income Net loss was $16.9 million.

Period: first quarter of 2024
Revenue: $2.4 million
Net income: Net loss was $16.9 million
Result: reported results

Exact text from the filing

Financial Results First Quarter 2024 ● Net loss was $16.9 million for the first quarter of 2024 compared to $28.2 million for the first quarter of 2023. ● Total revenue was $2.4 million for the first quarter of 2024 compared to $2.5 million for the first quarter of 2023. The decrease was primarily driven by lower contract research revenue during the three months

View on SEC.gov

Browse all earnings releases →

Aclaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-007055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.